Silence Therapeutics (Silence Therapeutics) Interest Expense : $-2.10 Mil (TTM As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Silence Therapeutics Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Silence Therapeutics's interest expense for the three months ended in Dec. 2023 was $ 0.08 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.10 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Silence Therapeutics's Operating Income for the three months ended in Dec. 2023 was $ -16.83 Mil. Silence Therapeutics's Interest Expense for the three months ended in Dec. 2023 was $ 0.08 Mil. Silence Therapeutics did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Silence Therapeutics Interest Expense Historical Data

The historical data trend for Silence Therapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Silence Therapeutics Interest Expense Chart

Silence Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-0.04

-0.02

-0.01

-0.06

-0.04

Silence Therapeutics Quarterly Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense	Get a 7-Day Free Trial															-0.02	-1.04	-1.13	-0.01	0.08

Silence Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.10 Mil.

Silence Therapeutics (NAS:SLN) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Silence Therapeutics's Interest Expense for the three months ended in Dec. 2023 was $0.08 Mil. Its Operating Income for the three months ended in Dec. 2023 was $-16.83 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $0.12 Mil.

Silence Therapeutics's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

The higher the ratio, the stronger the company's financial strength is.

Silence Therapeutics (Silence Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Silence Therapeutics PLC (NAS:SLN) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

SLNCF:USA XRP2:Germany

Address

72 Hammersmith Road, London, GBR, W14 8TH

Website

https://www.silence-therapeutics.com

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid. its pipeline products are; SLN360 therapy designed to temporarily block a specific gene's message that would otherwise trigger an unwanted effect. By silencing the LPA gene, the levels of Lp(a) are lowered, which in turn is expected to lower the risk of heart diseases, heart attacks, and strokes, and SLN124 therapy aims to temporarily silence TMPRSS6, a gene that prevents the liver from producing a particular hormone that controls iron levels in the body hepcidin. As hepcidin increases, iron levels in the blood are expected to decrease, which may increase the production of healthy red blood cells, thereby reducing anemia.